Machine learning-guided QSAR screening of fluconazole analogs and FDA-approved drugs against Candida albicans, with docking, molecular dynamics, and ADMET analysis.

Authors

Hamza Age Daudo, Emmanuel Silva Marinho, Victor Moreira de Oliveira, Márcia Machado Marinho, Ribeiro Vasco Ribeiro

Published in

Molecular diversity. Aug 07, 2026. Epub Aug 07, 2026.

Abstract

Invasive candidiasis caused by Candida albicans is a critical-priority fungal disease associated with high mortality, and the increasing resistance to fluconazole underscores the urgent need for new antifungal agents. In this study, a machine learning (ML)-guided quantitative structure-activity relationship (QSAR) workflow was developed to prioritize fluconazole analogs and FDA-approved drugs with predicted antifungal activity against Candida, followed by a structure-based exploration of a cell wall target. Bioactivity (IC₅₀) data for the CHEMBL366 target were curated to 1000 compounds, encoded using Morgan fingerprints (ECFP4, 2048 bits), and used to benchmark 42 regression algorithms; the three best-performing tree ensemble models (Extra Trees, Gradient Boosting, and Bagging) were optimized with Optuna. The Extra Trees model achieved the best performance (test R² = 0.70; RMSE = 0.38), and the applicability domain (AD) covered approximately 93% of the test compounds. Consensus virtual screening of fluconazole analogs from the ZINC database and 1683 FDA-approved drugs prioritized two structurally related analogs (ZINC000299869729 and ZINC000299869730). Molecular docking against exo-β-(1,3)-glucanase (PDB ID: 1EQP), used as an exploratory mechanistic hypothesis, produced more favorable scores (- 9.1 to - 9.6 kcal/mol) than fluconazole (- 8.5 to - 8.9 kcal/mol). In 200 ns molecular dynamics simulations, ZINC000299869730 showed greater conformational stability, while ZINC000299869729 exhibited the most favorable MM/GBSA binding free energy (- 19.02 kcal/mol). pkCSM-based ADMET profiling predicted good intestinal absorption but also shared AMES mutagenicity and hepatotoxicity alerts, which would require mitigation through structural optimization. All findings are strictly in silico and require experimental validation of antifungal activity and safety.

PMID:
42568008
Bibliographic data and abstract were imported from PubMed on 08 Aug 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.